Comparative preclinical toxicology and pharmacology of isophosphoramide mustard, the active metabolite of ifosfamide

Cancer Chemotherapy and Pharmacology

Volumn 55, Issue 2, 2005, Pages 143-151

  Germann, N ^a   Urien, S ^a   Rodgers, Andrew H ^b   Ratterree, Marion ^c   Struck, Robert F ^d   Waud, William R ^d   Serota, David G ^e   Bastian, Gerard ^a   Jursic, Branko S ^f   Morgan, Lee Roy ^b  

^a CENTRE RENÉ HUGUENIN   (France)

^b DEKK TEC Incorporated   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^d SOUTHERN RESEARCH INSTITUTE   (United States)

^e MPI RESEARCH   (United States)

^f UNIVERSITY OF NEW ORLEANS   (United States)

Author keywords

Dogs; Isophosphoramide mustard; Mice; Monkey; Pharmacology toxicology; Rat

Indexed keywords

DRUG METABOLITE; IFOSFAMIDE; ISOPHOSPHORAMIDE MUSTARD;

ALLOMETRY; ANIMAL EXPERIMENT; ANOREXIA; BONE MARROW DEPRESSION; BONE MARROW TOXICITY; CONTROLLED STUDY; DEATH; DEFECATION DISORDER; DIGESTIVE SYSTEM FUNCTION DISORDER; DOG; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG INFUSION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG USE; EDEMA; FEMALE; INCUBATION TIME; KIDNEY TUBULE NECROSIS; LETHAL DOSE; LETHARGY; LIVER TOXICITY; MALE; MONKEY; MOUSE; NEPHROTOXICITY; NONHUMAN; PANCYTOPENIA; PREDICTION; PRIORITY JOURNAL; RAT; RESPIRATORY ARREST; REVIEW; SEDATION; SEIZURE; SEX; TREMOR;

ANIMALS; DOGS; FEMALE; LETHAL DOSE 50; MACACA MULATTA; MALE; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED C3H; PHOSPHORAMIDE MUSTARDS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY;

EID: 19944428423     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0894-y     Document Type: Review

References (13)

1. Bisagni G, Boni C, Mamenti AL, Moretti G, Rondini E, Sassi M, Zadro A, Salvodi L (1998) Ifosfamide bolus followed by five days continuous infusion in extensively pretreated patients with advanced breast cancer: a phase II study. Tumori 84:659-661
2. Blum RH, Edmonson J, Ryan L, Pelletier L (1993) Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Oncology Group. Cancer Chemother Pharmacol 31:s238-s240
3. Breil S, Martino R, Guard V, Malet-Martino M, Niemeyer U (2001) Identification of new aqueous chemical degradation products of isophosphoramide mustard. J Pharm Biomed Anal 25:669-678
4. Cosson VF, Fuseau E, Efthymiopoulos C, Bye A (1997) Mixed effect modeling of Sumatriptan pharmacokinetics during drug development: interspecies allometric scaling. J Pharmacokinet Biopharm 25:149-167
5. Hagemeister FB, Donato M (2001) Ifosfamide-based chemotherapy regimens in the treatment of lymphoma: the MD Anderson experience. Eur J Haematol 64:8-13
6. Kaijser GP, Beijnen JH, Rozendom E, Bult A, Underberg WJM (1996) Analysis of ifosforamide mustard, the active metabolite of ifosfamide, in plasma. J Chromatogr B 686:249-255
7. Kerbusch T, De Kraker J, Keizer HJ, Van Putten JW, Groen HJ, Jansen RL, Schellens JH, Beijnen JH (2001) Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet 40:41-62
8. Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH (1998) Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16:2500-2504
9. Springate JE (1997) Ifosfamide metabolite Chloroacetaldehyde causes renal dysfunction in vivo. J Appl Toxicol 17:75-79
10. Struck RF, Dykes DJ, Corbett T, Suling WJ, Trader MW (1983) Isophosphoramide mustard, a metabolite of isofosfamide with activity against murine tumours comparable to cyclophosphamide. Br J Cancer 47:15-20
11. Urien S (1995) Micropharm-K a microcomputer interactive program for the analysis and simulation of pharmacokinetics processes. Pharm Res 12:1225-1230
12. Zheng JJ, Chan KK, Muggia F (1994) Preclinical pharmacokinetics and stability of isophosphoramide mustard. Cancer Chemother Pharmacol 33:391-398
13. Morgan LR (2004) Phase 1 clinical trial of isophosphoramide mustard in advanced cancer. US Food and Drug Administration. IND 71,792